



Spermosens announces outcome of exercise of warrants series TO 4

Spermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the TO 4 series of warrants, issued in connection with the rights issue announced on 20 February 2024. The subscription price for the TO 4 warrants was set at SEK 0.15, determined prior to the issuance of new shares in the rights issue completed in November 2024. The warrants were available for subscription from 17 November 2025 to 1 December 2025. As the subscription price exceeded the prevailing market price, no subscriptions were received. Consequently, the anticipated increase in share capital and potential dilution for existing shareholders will not take place.

Spermosens earlier this year secured an investment of SEK 10.8 million through a directed share issue from a consortium of American and European strategic investors, as communicated on 4 March 2025. This investment and the full subscription of warrants series TO 5, as communicated 17 June 2025, ensure funding for the Company until mid 2026, after which Spermosens potentially may become cash flow positive, primarily through revenue generated from license agreements with established partners in the global Assisted Reproductive Technology (ART) market.

For further information, please contact:

Tore Duvold, CEO

Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science-driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision in evaluations by measuring sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatment strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.